Neurocrine Biosciences (NBIX) to Release Earnings on Thursday

Neurocrine Biosciences (NASDAQ:NBIX) is expected to be issuing its quarterly earnings data after the market closes on Thursday, February 6th. Analysts expect the company to announce earnings of $1.62 per share and revenue of $629.40 million for the quarter. Parties that wish to register for the company’s conference call can do so using this link.

Neurocrine Biosciences Trading Down 1.1 %

Neurocrine Biosciences stock opened at $150.10 on Tuesday. The stock has a market cap of $15.20 billion, a price-to-earnings ratio of 40.24 and a beta of 0.33. The company’s 50-day moving average price is $136.97 and its two-hundred day moving average price is $131.42. Neurocrine Biosciences has a 52 week low of $110.95 and a 52 week high of $157.98.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on NBIX. StockNews.com cut shares of Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a research note on Friday, November 1st. William Blair reaffirmed an “outperform” rating on shares of Neurocrine Biosciences in a research note on Monday, December 16th. HC Wainwright reaffirmed a “buy” rating and issued a $190.00 price objective on shares of Neurocrine Biosciences in a research note on Monday, December 16th. Barclays lifted their price objective on shares of Neurocrine Biosciences from $160.00 to $165.00 and gave the stock an “overweight” rating in a research note on Monday, December 23rd. Finally, Wedbush reiterated an “outperform” rating and issued a $148.00 target price on shares of Neurocrine Biosciences in a report on Monday, December 16th. Five research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $166.10.

Insider Activity at Neurocrine Biosciences

In other Neurocrine Biosciences news, insider Ingrid Delaet sold 1,091 shares of the stock in a transaction on Tuesday, December 17th. The stock was sold at an average price of $135.00, for a total transaction of $147,285.00. Following the transaction, the insider now owns 2,507 shares in the company, valued at $338,445. This trade represents a 30.32 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Kyle Gano sold 65,000 shares of the firm’s stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $141.50, for a total value of $9,197,500.00. Following the completion of the transaction, the chief executive officer now owns 135,392 shares in the company, valued at $19,157,968. The trade was a 32.44 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 214,799 shares of company stock worth $31,513,583. Company insiders own 4.30% of the company’s stock.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.